 HOLLISTER, Calif., June 29, 2021 GLOBE NEWSWIRE -- Alpha Teknova, Inc. Teknova Nasdaq: TKNO, a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that on June 29, 2021, it closed its previously announced initial public offering of 6,900,000 shares of its common stock, at a price to the public of 16.00 per share. The closing included 900,000 shares sold upon full exercise of the underwriters option to purchase additional shares of common stock in the offering. All of the shares of common stock were offered and sold by Teknova. 